Navigation Links
Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
Date:12/9/2008

es up to an MTD of 20 ng/kg/min. Dose escalation was limited by symptoms of hypotension observed at 30 ng/kg/min, which represents a dose of approximately 3- to 6-fold above the anticipated therapeutic range.

Effects on Renal Function

Enhancement of renal function by CD-NP was observed at doses well below the MTD. Notably, no clinically limiting changes in blood pressure were observed at the doses showing the most favorable renal effects.

Renal function from evaluable patients was assessed via biomarkers including serum creatinine and creatinine clearance, the most frequently used surrogate measure of glomerular filtration rate (GFR) and renal function. CD-NP treatment resulted in a statistically significant reduction of serum creatinine. After a 24-hour infusion of CD-NP at 3 ng/kg/min, serum creatinine was reduced by 10% (p=0.03). Infusions of 10 and 20 ng/kg/min resulted in serum creatinine reductions of 10% and 7%, respectively. These changes translated to a statistically significant increase in creatinine clearance using the Cockcroft-Gault formula, with infusions of CD-NP at 3, 10 and 20 ng/kg/min resulting in increases of 10% (p=0.01), 9% (p=0.02) and 7%, respectively.

Consistent with its effect on creatinine clearance, CD-NP elicited a statistically significant reduction of cystatin C, another biomarker of renal function. Infusions of CD-NP at 3, 10, and 20 ng/kg/min resulted in reductions of cystatin-c of 5% (p=0.05), 9% (p=0.05) and 4%, respectively.

Infusion with CD-NP resulted in diuresis similar to that observed with furosemide, a common diuretic used frequently in the management of heart failure patients. The average total urine volume during the 24-hour infusions of CD-NP at 3, 10 and 20 ng/kg/min was 2,738 ml. By comparison, during the 24-hour period prior to CD-NP infusion in which patients received standard doses of furosemide, the avera
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
2. Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics
3. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
4. FDA Accepts Cell Therapeutics Zevalin sBLA and Grants Priority Review
5. Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides
6. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
7. Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug
8. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
9. TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
10. Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results
11. Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... 2014 HealthTronics, Inc. , ... radiology products and services, has signed a distribution ... Clinicon Corporation for its high precision laser ... minimally invasive, mobile, surgical technology—offering more choices for ... agreement, HealthTronics will make available Clinicon’s FDA-cleared SureLase™ ...
(Date:9/19/2014)... simple. From crop yields to disease risks, the biological ... "complex traits." Just as for heightthe textbook example of ... disease are shaped by multiple genetic and environmental influences, ... track down such genes, geneticists typically mate two individuals ... and a small mouseand then study their descendents, looking ...
(Date:9/19/2014)... San Jose, California (PRWEB) September 19, 2014 ... – Nanotechnology and its potential to revolutionize the ... government agencies, multinational corporations and small start-ups. The ... government funded research projects largely due to the ... capital investments. Government budgets earmarked for this evolving ...
(Date:9/19/2014)... , Sept. 19, 2014  Nektar Therapeutics ... from preclinical studies characterizing the analgesic profiles of ... kappa opioid receptor agonist molecules. The preclinical research ... medicinal chemistry platform. The analgesic properties ... the medical literature. 1,2 Kappa opioid receptors ...
Breaking Biology Technology:HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3Want to link genes to complex traits? Start with more diversity 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5
... Transgenomic, Inc. (OTC/BB: TBIO) announced today ... company,s high-sensitivity cancer mutation assays using two proprietary ... studies will be presented at the American Association ... April 2-6, 2011. "BLOCker-Sequencing and Ice ...
... New Haven, Conn.Fuel cells have been touted as a ... in everything from cars to computers. But ... their lack of endurance. Over time, the catalysts used ... the chemical reaction that converts fuel into electricity. In ...
... March 31, 2011 Reportlinker.com announces that ... in its catalogue: Molecular ... The technologies that constitute ... in situ hybridization (FISH), second-generation biochips and ...
Cached Biology Technology:Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting 2Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting 3Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting 4Novel nanowires boost fuel cell efficiency 2Reportlinker Adds Molecular Diagnostics Markets 2Reportlinker Adds Molecular Diagnostics Markets 3Reportlinker Adds Molecular Diagnostics Markets 4Reportlinker Adds Molecular Diagnostics Markets 5Reportlinker Adds Molecular Diagnostics Markets 6Reportlinker Adds Molecular Diagnostics Markets 7Reportlinker Adds Molecular Diagnostics Markets 8Reportlinker Adds Molecular Diagnostics Markets 9Reportlinker Adds Molecular Diagnostics Markets 10Reportlinker Adds Molecular Diagnostics Markets 11Reportlinker Adds Molecular Diagnostics Markets 12Reportlinker Adds Molecular Diagnostics Markets 13Reportlinker Adds Molecular Diagnostics Markets 14Reportlinker Adds Molecular Diagnostics Markets 15Reportlinker Adds Molecular Diagnostics Markets 16Reportlinker Adds Molecular Diagnostics Markets 17Reportlinker Adds Molecular Diagnostics Markets 18
(Date:9/18/2014)... the fish world, are the ideal animal in which ... moved from the ocean into tens of thousands of ... changing their skeleton to adapt to the new environment. ... sticklebacks now have turned up one of the genes ... change in that gene,s regulation in a freshwater population ...
(Date:9/18/2014)... has found clownfish larvae can swim up to 400 kilometres ... to cope with environmental change. , Clownfish spend their entire ... as babies they must wander the open ocean, says study ... for Coral Reef Studies (Coral CoE) at James Cook University. ... but now we,ve been given a rare glimpse into how ...
(Date:9/17/2014)... From accessible and affordable health care to reproductive ... depend on the ability of people to identify ... openly and respectfully, and find the most defensible ... practices to support these societal conversations?, The Hastings ... of Bioethical Issues have teamed up to publish ...
Breaking Biology News(10 mins):Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3Nemo's epic journey to find a new home 2Why bioethics literacy matters 2Why bioethics literacy matters 3
... Researchers at the University of Pennsylvania School of ... with an increased risk of testicular cancer. Testicular cancer is ... among non-Hispanic Caucasian men has doubled in the last 40 ... men in the United States each year. The discovery, published ...
... Carolina State University engineers have created a non-toxic "wrinkled" ... of troublesome barnacles during 18 months of seawater tests, ... of dollars in cleaning and fuel costs. The ... in the Department of Chemical and Biomolecular Engineering, and ...
... ultrafast laser pulses to slice off pieces of ... engineers at the University of Michigan have gained ... division. Their findings could help scientists better ... in plants, fungi, and animalsincluding those in the ...
Cached Biology News:Penn researchers discover genetic risk factor for testicular cancer 2Penn researchers discover genetic risk factor for testicular cancer 3Nontoxic hull coating resists barnacles, may save ship owners millions 2Slicing chromosomes leads to new insights into cell division 2
Recognizes Kir4.1. The epitope does not share homology with any other known proteins.,SPECIES REACTIVITIES: The antibody is also expected to work with mouse and human due to sequence homology. Oth...
... Development kit contains the basic components required ... measure natural and recombinant mouse Dickkopf homolog-1 ... Each kit contains sufficient materials to run ... that the following conditions are met: ...
HIV-1 TAT (vN-21)...
Presenilin-1, N-terminus....
Biology Products: